JSJelena Saliën

Jelena Saliën

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jelena Saliën has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • More Than a Glow: How Cyanine Dyes Shape Tracer Pharmacokinetics

    by Jelena Saliën, Anthony Romieu, Franck Denat, Victor Goncalves, Sophie Hernot

    Fluorescence molecular imaging stands as a crucial method for tracking physiological or pathological biomarkers within living organisms. In clinical practice, this technology is increasingly applied to assist physicians in decision‐making during interventional or surgical procedures. To develop imaging tracers, targeting molecules are covalently labeled with fluorescent organic dyes. Yet, it is often overlooked that such modifications to the molecule can influence and even alter its pharmacokinetics and distribution within the body. This review aims to provide an overview of the advancements in fluorophores commonly used in translational and clinical fluorescence molecular imaging, with a specific focus on long‐wavelength cyanine dyes. Additionally, we will illustrate how the fluorophore's structure and labeling parameters influence the in vivo behavior of molecules, underscoring the importance of considering these aspects when designing fluorescent tracers.

  • More Than a Glow: How Cyanine Dyes Shape Tracer Pharmacokinetics

    by Jelena Saliën, Anthony Romieu, Franck Denat, Victor Goncalves, Sophie Hernot

    Fluorescence molecular imaging stands as a crucial method for tracking physiological or pathological biomarkers within living organisms. In clinical practice, this technology is increasingly applied to assist physicians in decision‐making during interventional or surgical procedures. To develop imaging tracers, targeting molecules are covalently labeled with fluorescent organic dyes. Yet, it is often overlooked that such modifications to the molecule can influence and even alter its pharmacokinetics and distribution within the body. This review aims to provide an overview of the advancements in fluorophores commonly used in translational and clinical fluorescence molecular imaging, with a specific focus on long‐wavelength cyanine dyes. Additionally, we will illustrate how the fluorophore's structure and labeling parameters influence the in vivo behavior of molecules, underscoring the importance of considering these aspects when designing fluorescent tracers.


  • In vivo Fluorescent Molecular Imaging Using Nanobodies Labeled with Next-Generation FNIR-Tag-Dyes

    by Dora M. Chigoho, Marcus C. M. Stroet, Jelena Saliën, Sofie Pollenus, Dong-Hao Li, Martin Schnermann, Sophie Hernot

  • Open Access

    Chelator Conjugation Chemistry Matters: Squaramide Linker Enhances Tumor Contrast in 68 Ga-labeled Anti-CEA Nanobody Tracer

    by Jelena Saliën, Sam Floru, Michiel Van Hove, Tessa De Pauw, Romane Vizier, Michael Claron, Jessica Bridoux, Victor Goncalves, Franck Denat, Sophie Hernot

    Complexation of radiometals by chelators allows for convenient radiolabeling of molecules of interest for the preparation of radiopharmaceuticals. In the chelator family, triazacyclononane (TACN)-based macrocycles have been used ubiquitously over the last 40 years, and many bifunctional derivatives have been developed. Despite this diversity, researchers commonly make their chelator selection based on practical factors like (commercial) availability and compatibility with the desired radionuclide, acknowledging that these considerations often outweigh achieving ideal in vivo pharmacokinetics. In this study, we generated and preclinically evaluated four gallium-68-labeled anti-CEA Nanobody-based tracers carrying different TACN-derivatives: p-NCS-Bn-NOTA, p-NCS-Bn-NODAGA, NODAGA-Sq, and NODAGA-NHS. Since the macrocyclic chelator is highly similar in these derivativesthey all present a NOTA ((1,4,7-triazacyclononane-1,4,7-triacetic acid) scaffoldthe effect of the bioconjugation handle on the pharmacokinetic properties could be examined in a side-by-side comparison. The four PET tracers were prepared and could easily be labeled with gallium-68. Then, their stability, target affinity, and hydrophilic character were determined in vitro. Next, their in vivo biodistribution was evaluated using PET/CT imaging in a subcutaneous tumor mouse model. Despite their high structural similarity, notable differences in pharmacokinetics were observed in vivo, more specifically in the tumor and liver signal. Tracer [68Ga]­Ga-NODAGA-Sq-NbCEA was found to be the best performer in our study, with a tumor signal 1.6-fold higher than [68Ga]­Ga-NODAGA-NbCEA and a tumor-to-liver ratio 1.5-fold and 1.7-fold higher than that of [68Ga]­Ga-NOTA-Bn-NCS-NbCEA and [68Ga]­Ga-NODAGA-Bn-NCS-NbCEA, respectively. By comparing this tracer to the negative control [68Ga]­Ga-NODAGA-Sq-R3b23, specific tumor targeting was demonstrated.


  • Open Access

    In vivo Fluorescent Molecular Imaging Using Nanobodies Labeled with Next-Generation FNIR-Tag Dyes

    by Dora M. Chigoho, Marcus C.M. Stroet, Jelena Saliën, Sofie Pollenus, Dong-Hao Li, Martin Schnermann, Sophie Hernot

    Purpose Fluorescently labeled Nanobodies (Nbs) provide rapid, specific, and high-contrast molecular imaging capabilities, making them well suited for applications such as fluorescence-guided surgery. As dye properties can sbstantially influence tracer performance, this study evaluated three next-generation FNIR-Tag dyes, each conjugated to an anti-EGFR Nb. Procedures The anti-EGFR Nb 7D12 was conjugated to FNIR-Tag-1.0, FNIR-Tag-766 or FNIR-Tag-804, and characterized in vitro. In vivo imaging and biodistribution studies were performed to assess pharmacokinetics, tumor uptake, tumor-to-background ratios, contrast-to-noise ratios, and renal clearance. Results All three Nb-based tracers exhibited similar overall pharmacokinetic behavior, characterized by fast tumor accumulation, rapid clearance from blood and non-target tissues, and predominant renal elimination. 7D12–FNIR-Tag-1.0 demonstrated slightly higher tumor uptake, whereas 7D12–FNIR-Tag-766 produced marginally improved tumor-to-background and contrast-to-noise ratios. In contrast, 7D12–FNIR-Tag-804 yielded significantly lower tumor signal intensity, although its imaging contrast remained comparable due to proportionally reduced background fluorescence. Despite differences in dye net charge, no substantial variation in kidney retention was observed over 24 h. Microscopic analysis revealed distinct renal handling: 7D12–FNIR-Tag-766 showed partial endosomal internalization within proximal tubule cells, while 7D12–FNIR-Tag-1.0 remained primarily luminal. Conclusions FNIR-Tag–labeled Nbs enable effective tumor visualization as early as 1 h post-injection. Although overall pharmacokinetics were comparable across dyes, differences in tissue uptake, intrinsic brightness, and compatibility with imaging system optics can influence detection sensitivity and should inform dye selection for clinical imaging applications.

  • Open Access

    Reflect: reporting guidelines for preclinical, translational and clinical fluorescence molecular imaging studies

    by Bas Keizers, Marcus C. M. Stroet, Meedie Ali, Sam Floru, Jelena Saliën, Laura Mezzanotte, Edward J. Delikatny, Summer L. Gibbs, Stefano Giuliani, Sylvain Gioux, et al.

    Fluorescence molecular imaging (FMI) is becoming a powerful tool to improve surgical precision and diagnostics. Although significant advances have been made in imaging technology and contrast agents, debate continues regarding suitable standards for FMI. Standardizing all FMI aspects is crucial for adoption in clinical procedures and routine practice. Currently, the lack of clear-cut guidelines on FMI study reporting complicates comparison between studies and impedes standardization. This work presents community-driven REFLECT guidelines for FMI study reporting for fluorescence-guided surgery and interventions, covering preclinical, translational, and clinical studies. It aims to improve quality of reporting, enable comparison between studies, and enhance interpretation of results. The resulting structured checklist encompasses all essential details for reporting on the contrast agent, imaging device, imaging protocol, and image processing and analysis methods. Adoption of this framework is encouraged to enhance reproducibility and establish alignment with standardization efforts in the field - thus fostering advancements in FMI.


  • A Comparative Study on the Effect of Near-Infrared Fluorescent Dyes on the Pharmacokinetic Behavior of Nanobody-Based Tracers for In Vivo Imaging

    by Noemi B. Declerck, Sofie Declercq, Pieterjan Debie, Julie Du Ville, Łukasz Mateusiak, Jelena Saliën, Marcus C. M. Stroet, Michael P. Luciano, Dong-Hao Li, Martin J. Schnermann, et al.

    Near-infrared fluorescent molecular imaging is increasingly being used as a tool to guide intraoperative decision-making. While research into novel fluorescent molecular tracers often prioritizes the targeting moiety, compelling evidence indicates that the choice of fluorophore can substantially influence tracer pharmacokinetics. In this study, tumor-specific Nanobodies were conjugated with four widely used dyes─IRDye800CW, ZW800-1, FNIR-Tag, and s775z-, and a side-by-side comparison of their in vivo biodistribution and tumor targeting was performed. Nanobodies labeled with FNIR-Tag or s775z showed markedly superior results compared to those labeled with IRDye800CW or ZW800-1, demonstrating strong tumor accumulation as early as 1 h postinjection and minimal background signal, particularly in the liver. The effect of increasing dye density on tracer pharmacokinetics was also assessed. Compared with Nbs labeled with a DOL of 1, those with an average of 2 dyes exhibited higher mean fluorescent tumor signals but no improvement in tumor-to-background ratios, owing to increased background signals.